Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics

<p>Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today announced that its joint venture partner, Virion Therapeutics, LLC, is now enrolling patients in its Phase 1b study for a first-in-class treatment of chronic Hepatitis […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/ocean-biomedical-nasdaq-ocea-announces-enrollment-of-patients-for-phase-1b-study-for-chronic-hepatitis-b-treatment-in-50-50-joint-venture-with-virion-therapeutics/">Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>